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Successful management of breast cancer in the metastatic setting is often confounded by resistance to chemotherapeutics, in
particular anthracyclines and taxanes. The limited number of eﬀective treatment options for patients with more aggressive
biological subtypes, such as triple-negative metastatic breast cancer, is especially concerning. As such, a therapy clinically proven
to be eﬀective in this subtype would be of great value. Ixabepilone, a novel synthetic lactam analog of epothilone B, demonstrated
better clinical outcomes in metastatic disease, particularly in triple-negative breast cancer. Most recently, studies have shown
the activity of ixabepilone in the neoadjuvant setting, suggesting a role for this drug in primary disease. Notably, treating in
the neoadjuvant setting might allow clinicians to explore the predictive value of biomarkers and response to treatment, as
pharmacogenomic approaches to therapy continue to evolve. In this article, we review the eﬃcacy and safety data of ixabepilone
as a monotherapy and as a component of combination therapy for metastatic and primary breast cancer.
1.Introduction
Breast cancer is the most prevalent malignancy in women
and in its metastatic state, the second most common cause of
mortality [1]. In 2011, an estimated 230,480 of women were
diagnosed with new cases of invasive breast cancer in the
United States and 39,520 died from the disease [2]. Despite
advances in treatment strategies, metastatic breast cancer
(MBC) remains incurable and the goals of therapy range
from symptom palliation to extending survival. Treatment
selectionisbasedonaseriesoffactorsincludingperformance
status, site of metastasis, and subtype of disease [3]. Breast
tumors can be classiﬁed into 5 intrinsic subtypes based on
diﬀerences in patterns of gene expression: (1) basal-like;
(2) human epithelial receptor-2-positive (HER2)/neu, also
knownasErbB2+;(3)luminal-likeA;(4)luminal-likeB;and
(5) the normal breast tissue-like subtype [4]. As such, breast
cancertreatmentscanbecategorizedas:(a)estrogenreceptor
(ER)-positive and thus, treatable by endocrine therapy; (b)
HER2 overexpressed/ampliﬁed, treatable with trastuzumab
or other HER2-targeted therapies; or (c) triple-negative
(TN), with no current speciﬁc therapeutic biomarker, typi-
cally treated with cytotoxic chemotherapy. This review will
outline the treatment strategies in the management of MBC
and focus on the role of novel cytotoxic agents, particularly
ixabepilone, in this disease.
2. The Management of MBC
Breast cancer tumor subtypes are characterized by diﬀerent
clinical outcomes [5]. Basal-like tumors are primarily ER-
negative, strongly associated with mutations in the breast
cancer susceptibility gene 1 (BRCA1), and have a very
poor clinical outcome. BRCA1 is a tumor suppressor that
functions in many DNA damage response pathways (i.e.,
homologous recombination and nonhomologous end-join-
ing during DNA double-strand break repair). HER2/neu
tumors are typiﬁed by overexpression of ErbB2 and genes
involved in the ras pathway [6]. Similar to basal-like tumors,
they are primarily ER-negative and associated with a poor
clinical outcome. Conversely, luminal-like A and B tumors
are primarily ER-positive, with luminal-like A providing2 Journal of Oncology
the best clinical outcome of all subtypes, whereas luminal-
like B tumors are associated with an intermediate outcome.
Tumors from patients with the normal breast tissue-like sub-
type tend to have the lowest expression of genes associated
with cell proliferation and thus would be expected to have a
favorable clinical outcome [7].
Managing MBC can be extremely challenging, as resis-
tance to standard-of-care chemotherapeutics (i.e., anthra-
cyclines and taxanes) is a major cause of treatment failure
[8–10]. Moreover, the widespread use of anthracycline and
taxane in the adjuvant setting theoretically contributes to
an increase of the proportion of patients with resistance to
these drugs for whom other eﬀective agents are necessary for
treatment of recurrent disease. This condition is particularly
relevant for patients with TN breast cancer, a subset of
disease associated with more aggressive features and higher
recurrence rate [11] .Th em o s tr e c e n ti n v e s ti ga ti o n se x p l o r e d
the various mechanisms of drug resistance and attempted
to develop agents that could target those survival path-
ways. Several preclinical models identiﬁed overexpression of
neuronal-β tubulin III and IV isotopes associated with resis-
tance to taxanes [12, 13]. These observations were conﬁrmed
in subsequent clinical studies in patients with MBC treated
with ﬁrst line paclitaxel further conﬁrming the critical role
of β tubulin in the development of drug resistance [14,
15]. More recently, poly(ADP-ribose) polymerase (PARP)
inhibitors were extensively evaluated for their activity and
clinical beneﬁt especially for women with TN disease, as
PARP inhibitors have shown promising results in mammary
tumor models [16, 17].
Although typically regarded as pro-survival under phys-
iological conditions, studies in which PARP1 was inhibited
during S-phase in BRCA1-a n dBRCA2-deﬁcient cells have
shownthatPARP1inhibitioncausesgenomicinstability,cell-
cycle arrest, and apoptosis, as these cells were defective in
homology-directed double-strand break repair mechanisms
[17–19] imparted by unmutated BRCA1.I m p o r t a n t l y ,h e r e -
ditary breast cancers due to mutations in BRCA1 are mainly
of the basal-like or TN subtypes suggesting the utility of
PARP1 inhibitors in treatment of patients with TN breast
cancer.
Early clinical results with the PARP1 inhibitor iniparib
(BSI-201) in 123 patients with TN breast cancer were en-
couraging and showed that the addition of iniparib to
treatment with gemcitabine plus carboplatin signiﬁcantly in-
creased median overall survival (OS, 12.3 versus 7.7 months;
P = 0.01), median progression-free survival (PFS, 5.9 versus
3.6 months; P = 0.01), and objective response rate (ORR,
52% versus 32%; P = 0.02) [20]. However, recent results
from a randomized phase 3 trial with 519 patients with TN
breast cancer did not conﬁrm these data; patients receiving
iniparib with gemcitabine and carboplatin experienced no
improvement in OS (11.8 versus 11.1 months; P = 0.284)
and only minor improvement in PFS (5.1 versus 4.1 months;
P = 0.027) compared with patients receiving chemotherapy
alone [21]. This study did not meet the prespeciﬁed signif-
icance criteria for PFS and OS; ongoing molecular analyses
of patients’ tumor samples may identify cancer subtypes
sensitive to PARP1 inhibition.
Novel cytotoxic agents would be particularly useful for
patients with anthracycline and/or taxane-resistant disease.
Eribulin and ixabepilone are microtubule-targeting agents
that have recently expanded the armamentarium of available
cytotoxic drugs in treatment of MBC.
Eribulin,asyntheticanalogofthemarinemacrolidehali-
chondrin B, was approved by the US Food and Drug Admin-
istration (FDA) and the European Medicines Agency for
the treatment of patients with MBC who have received at
least 2 prior chemotherapy regimens for late-stage disease.
The approval was based on results from a phase 3 trial
(EMBRACE) which compared eribulin monotherapy with
the physician’s choice of treatment in 762 patients with an-
thracycline- and taxane-pretreated locally recurrent breast
cancerorMBC[22].P atientsreceiv ed2to5previouschemo-
therapy regimens, including at least 2 regimens for recurrent
or MBC. The physician’s choice included any monotherapy,
most commonly vinorelbine, gemcitabine, or capecitabine.
Eribulin signiﬁcantly improved median OS compared with
the physician’s treatment choice (13.1 versus 10.6 months;
P = 0.041) and also produced a higher response rate (12%
versus 5%; P = 0.002) but did not show longer PFS (3.7
versus 2.2 months; P = 0.137) on independent review.
EMBRACE was the ﬁrst phase 3 study demonstrating a sur-
vival beneﬁt for single-agent therapy in heavily-pretreated
MBC patients.
Ixabepilone is a semi-synthetic lactam analog of epo-
thilone B, which belongs to a class of naturally occurring,
pro-apoptotic, antineoplastic microtubule-stabilizing com-
pounds [23, 24]. The epothilones, although structurally un-
related to the taxanes, bind to the taxane-binding domain of
microtubules. However, the mechanism by which each agent
binds to these sites is diﬀerent [25] and ixabepilone thus
maintains activity against paclitaxel-resistant cell lines [26,
27]. Moreover, ixabepilone demonstrated potent activity in
ax e n o g r a f tm o d e lw i t hβIII-tubulin overexpression (Pat-21
breast cancer), and in two xenograft models with an over-
expression of drug eﬄux transporters (Pat-7 ovarian cancer
and HCTVM46 colon cancer) [28–30].
3. Ixabepiloneand ItsApproved Indications
Among the epothilones, ixabepilone has undergone the most
extensive clinical development [31]. Preclinical trials in
mouse xenograft models demonstrated that the maximum
tolerated dose for ixabepilone was 10mg/kg [32]. Results
from clinical trials of patients treated with ixabepilone
40mg/m2 demonstrated that the exposure was comparable
to that of mice treated with ixabepilone 10mg/m2, and that
40mg/m2 oﬀered clinically signiﬁcant antitumor activity
[33]. After determining a clinically eﬀective dose, phase I/II
trialsinpatientswithsolidtumorsinvestigatedseveraldosing
schedules of the Cremophor-based ixabepilone formulation
[34]. Subsequent trials described in the next section have
identiﬁed doses that led to the FDA approval of ixabepilone
for the treatment of metastatic or locally advanced breast
cancer in patients after failure of an anthracycline and
a taxane (in combination with capecitabine) and as aJournal of Oncology 3
monotherapy after failure of an anthracycline, a taxane, and
capecitabine [35].
4. Ixabepiloneas a Monotherapy or in
Combination withCapecitabine:Trials081,
046, and048
Three pivotal clinical trials, a phase 2 trial (081) and 2
phase 3 trials (046 and 048), have investigated the eﬃcacy
of ixabepilone as a monotherapy and in combination with
capecitabine in patients with MBC [36–38].
4.1. Trial 081. The single-arm phase 2 trial 081 assessed the
eﬃcacy of ixabepilone (40mg/m2 intravenous [IV] over 3
hours every 3 weeks) in women with MBC who were heavily
pretreated with an anthracycline, a taxane, and capecitabine.
In this trial, patients had signiﬁcant baseline disease and the
majority (88%) had received up to 3 prior therapies in the
metastatic setting. Ixabepilone demonstrated ORR among
113 response-assessable patients of 11.5% (95% conﬁdence
interval[CI],6.3%–18.9%)asdeterminedbyanindependent
radiology facility. The investigator-assessed ORR among all
126 patients was 18.3% (95% CI, 11.9%–26.1%). Additional
13% (95% CI, 7.6%–20.9%) of treated patients demon-
strated durable (≥6 months) stable disease. Median PFS was
3.1 months (95% CI, 2.7–4.2 months) [36]. The tolerability
proﬁle of ixabepilone was acceptable, as treatment-related
adverse events were manageable and mostly grade 1 to 2.
Selected grade 3 to 4 hematologic, treatment-related adverse
events included neutropenia (54%) and fatigue/asthenia
(14%), whereas peripheral neuropathy was the most com-
mon nonhematologic adverse event. In summary, the results
demonstrated that ixabepilone monotherapy has clinically
meaningful antitumor activity with a manageable safety
proﬁle in patients with MBC resistant to an anthracycline,
a taxane, and capecitabine.
4.2. Trials 046 and 048. These 2 randomized, open-label
phase 3 trials assessed the eﬃcacy of ixabepilone (40mg/m2
IV over 3 hours every 3 weeks) in combination with cap-
ecitabine (2000mg/m2 orally on days 1–14 every 3 weeks)
versus capecitabine alone (2500mg/m2) on the same sched-
ule. In total, 1973 (N = 752 [046] and = 1221 [048]) pa-
tients with MBC heavily pretreated and previously exposed
toananthracyclineand/orresistanttoataxane,wereassessed
[37, 38]. The primary endpoint of these studies was PFS.
In trial 046, PFS associated with ixabepilone in combi-
nation with capecitabine was superior to capecitabine as a
single agent (hazard ratio [HR] = 0.75; 95% CI, 0.64–0.88;
stratiﬁed log-rank P = 0.0003). Median PFS was prolonged
to 5.8 months (95% CI, 5.45–6.97 months) for ixabepilone
incombinationwithcapecitabinecomparedwith4.2months
(95% CI, 3.81–4.50) for capecitabine alone; these data were
consistent with investigator-assessed median PFS (5.3 versus
3.8 months; P = 0.0011). The ORR was also greater in the
combination arm by independent assessment (35% versus
14%; P<0.0001) and by investigator assessment (42%
versus 23%) [38]. In trial 048, median PFS (6.2 versus 4.4
months; P = 0.0005) for ixabepilone in combination with
capecitabine, compared with capecitabine alone, was similar
to the median PFS observed in trial 046 [37]. Investigator-
assessed ORRs were also consistent with those reported in
study 046 (43% versus 29%).
Ixabepilone plus capecitabine was well tolerated in the
phase 3 trials, with a manageable toxicity proﬁle. The most
commongrade3/4adverseeventinthecombination-therapy
arm was peripheral neuropathy, occurring in 23% and 24%
of patients in trials 046 and 048, respectively, compared with
0% and 1% of patients in the capecitabine-monotherapy
arms, respectively. Fatigue (9–12% versus 3%), myalgia
(4–8% versus <1%), and asthenia (6-7% versus 1%) also
occurred more frequently in the combination-therapy arm.
5. Ixabepilonein First-LineTherapy
5.1. Pooled Analysis from Trials 046 and 048. Post-adjuvant
breast cancer patients who progress after anthracyclines and
taxanes require eﬀective ﬁrst-line therapies for the treatment
of their metastatic disease. This is of particular importance
to patients whose tumors demonstrate primary resistance to
anthracyclines and taxanes and for those whose anthracy-
cline cumulative exposure is limited by cardiotoxicity. A pre-
deﬁned subgroup analysis of patients with TN breast cancer
(N = 443)—based on the pooled analysis of trials 046 and
048 (N = 1973)—showed that ixabepilone in combination
with capecitabine signiﬁcantly improved PFS (4.2 versus 1.7
months) and increased ORR (31% versus 15%) compared
with capecitabine alone [31]. In another analysis from trials
046 and 048, a prespeciﬁed subset of post-adjuvant, rapidly
relapsing patients (N = 293; patients relapsed less than 1
year after completing neoadjuvant/adjuvant therapy) were
pooled to assess the eﬃcacy and safety of ixabepilone in
combination with capecitabine compared with capecitabine
alone. Prespeciﬁcation of the subset allowed patients to be
followed prospectively and because both trials shared similar
trial designs and patient populations, the individual subset
data were pooled to increase the statistical power [39].
In patients who received ﬁrst-line therapy, ixabepilone in
combination with capecitabine improved median PFS by 2.8
months compared with capecitabine alone (HR = 0.58; 95%
CI,0.45–0.76;stratiﬁedlog-rankP<0.0001).Similarly,there
was nearly a 2-fold increase in ORR of patients treated with
ixabepilone in combination with capecitabine compared
with capecitabine alone. Hematologic (i.e., neutropenia and
febrile neutropenia) and nonhematologic toxicities (any per-
ipheral neuropathy) associated with the combination were
manageableandsimilartothoseobservedinthepooledover-
all population. Compared with capecitabine alone, ixabepi-
lone plus capecitabine was an eﬀective ﬁrst-line treatment
forpost-adjuvant,rapidlyprogressingpatientswithclinically
meaningful improvements in ORR and PFS [39].
5.2. Ixabepilone Combinations in MBC
5.2.1. Ixabepilone + Bevacizumab. Preliminary data from
preclinicaltrialsshowedstrongsynergisticantitumoractivity4 Journal of Oncology
of ixabepilone in combination with bevacizumab [40].
Recently, a randomized phase 2 trial investigated this combi-
nation as ﬁrst-line therapy for MBC by comparing a weekly
ixabepilone-based regimen (16mg/m2 weekly for 3 weeks,
every 4 weeks, plus bevacizumab 10mg/kg every 2 weeks;
arm A [N = 46]) and an every-3-week ixabepilone-based
regimen (40mg/m2 e v e r y3w e e k sp l u sb e v a c i z u m a b1 5m g /
kgevery3weeks;armB[N = 45]).Theseexperimentaltreat-
ments were compared with a combination of paclitaxel and
bevacizumab (90mg/m2 weekly, plus bevacizumab at the
same dose and schedule as arm A; arm C [N = 32]) [41].
Final results showed that ORRs were not signiﬁcantly diﬀer-
ent among the 3 arms (ORR of 48% [32.9–63.1]; 71% [55.7–
83.6]; 63% [43.7–78.9] in arms A, B, C, resp.). Similarly,
median PFS also did not show signiﬁcant diﬀerences (9.6
months [6.1–11.7]; 11.9 months [8.7–14.7]; 13.5 months
[10.0–18.2] in arms A, B, C, resp.) [41], suggesting that
the every-3-week schedules of ixabepilone are as eﬀective
as paclitaxel when combined with bevacizumab. The most
signiﬁcant grade 3 or 4 treatment-related nonhematologic
and hematologic adverse events included peripheral sensory
neuropathy (18%, 24%, 25% in arms A, B, C, resp.) and
neutropenia (16%, 60%, 22% in arms A, B, C, resp.); feb-
rile neutropenia rates were ≤2.2% in all arms. Ixabepi-
lone did not appear to exacerbate the toxicity proﬁle of
bevacizumab, as the rates of adverse events were similar to
those observed with ixabepilone alone at these scheduled
doses. Furthermore, the clinical eﬃcacy and tolerability pro-
ﬁle demonstrated with ixabepilone in combination with be-
vacizumab—weekly or every 3 weeks—was comparable to
that observed in the phase 3 Eastern Cooperative Oncology
Group (ECOG) 2100 trial of bevacizumab in combination
with paclitaxel versus paclitaxel alone [42].
Although the phase 2 trial discussed herein assessed the
eﬀect of ixabepilone in combination with bevacizumab, it
was the ﬁrst to compare weekly ixabepilone to the approved
every-3-week schedule. Final results from a comparative
phase 2 trial of weekly (16mg/m2) or every-3-week ixabepi-
lone (40mg/m2) for 176 patients with MBC suggested that
both schedules have an acceptable safety proﬁle [43]. The
weekly versus every-3-week schedule produced ORR of
8% (95% CI, 2.5–16.8) versus 14% (95% CI, 6.9–24.1),
respectively (P = 0.23); median OS of 13.4 months versus
15.0 months, respectively (P = 0.21); and median PFS of 2.8
months versus 5.1 months, respectively (P = 0.09). These
results indicate a trend towards a longer median PFS with
every-3-week, compared with weekly ixabepilone. However,
the weekly schedule was better tolerated; grade 3/4 adverse
events were reported in 28% of patients treated with the
weekly schedule and in 69% of patients treated with the
every-3-weekscheduleandincludedneuropathy(11%versus
20%) and neutropenia (7% versus 40%).
5.2.2. Ixabepilone + Trastuzumab + Carboplatin. Previous
studies have shown that the addition of trastuzumab
to chemotherapy improves the clinical eﬃcacy proﬁle of
patients with MBC whose tumors demonstrate overexpres-
sion or ampliﬁcation of HER2. In one study, the addition of
trastuzumab to paclitaxel was associated with a signiﬁcant
improvement in ORR (38% versus 16%, P<0.001)
[44, 45]. Likewise, in a phase 3 trial that evaluated the
role of carboplatin as a treatment for HER2-positive MBC,
the addition of carboplatin to weekly trastuzumab and
paclitaxel (175mg/m2 IV every 3 weeks) was associated with
a signiﬁcantly higher ORR (57% versus 36%, P = 0.03) and
extended PFS (10.7 months versus 7 months, P = 0.03)
[46, 47].
Phase 1/2 trials have previously established the eﬃcacy
of ixabepilone monotherapy (weekly and every 3 weeks) for
patients with MBC [36, 44, 46–51]. As part of combination
therapy, phase 1 trials have demonstrated tolerability for
ixabepilone in combination with carboplatin [44, 47, 52],
and a phase 2 trial of ixabepilone in combination with
trastuzumab demonstrated clinically meaningful results in
patients with HER2-positive MBC [53]. As such, the ECOG
conducted a phase 2 trial (E2103) of weekly ixabepilone in
combinationwithcarboplatinandtrastuzumabasaﬁrst-line
treatment for patients with HER2-positive MBC [44]. The
primary endpoint of the trial was to determine if an ORR of
at least 75% was attainable with the combination. A total of
59 patients were treated with weekly ixabepilone 15mg/m2
IV and carboplatin (area under the curve = 2I Vo nd a y s1 ,
8, and 15 of a 28-day cycle for a maximum of 6 cycles), plus
weekly trastuzumab (4mg/kg loading dose, then 2mg/kg IV
during chemotherapy, then 6mg/kg IV every 3 weeks) until
disease progression; 39 patients were centrally conﬁrmed to
overexpress HER2 (3+ by immunohistochemistry or gene
ampliﬁcation by ﬂuorescent in situ hybridization).
Forallpatientstreated,theORRwas44%(95%CI,31%–
58%)andforthosepatientswhohadoverexpressedorampli-
ﬁed HER2, ORRs were comparable (42%; 95% CI, 26%–
58%). Treatment-related toxicities were found to be manage-
able and low-grade, with grade 3 to 4 neutropenia (49.1%)
among the most severe of hematologic toxicities. Notably,
there were no reports of febrile neutropenia. Nonhemato-
logic treatment-related adverse events were predominantly
mild, with fatigue (11.9%) and sensory neuropathy (6.8%)
among the most common grade 3 toxicities. Only 1 patient
(1.7%) experienced a grade 4 nonhematologic adverse event
of thrombosis/embolism. Although clinically eﬀective as a
ﬁrst-line therapy for HER2-positive MBC, the addition of
ixabepilone to carboplatin and weekly trastuzumab did not
meet the study primary endpoint. However, the regimen was
well tolerated with an eﬃcacy and toxicity proﬁle consistent
with that of paclitaxel in combination with carboplatin and
trastuzumab.
6. Ixabepiloneas a NeoadjuvantTherapy for
Breast Cancer
With the availability and access to pretreatment biopsy, the
neoadjuvant treatment setting oﬀers the ideal opportunity
to identify predictive biomarkers for novel therapeutics and
identify single agents or combination regimens likely to
impact prognosis. In fact, information regarding biomarkers
obtained from tumor biopsies can be assessed and comparedJournal of Oncology 5
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with the pathologic complete response in both breast and
lymph nodes (pCR) or in the breast only (pCRB)—an end-
point strongly associated with disease-free and overall
patient survival [54–57]. Based on the encouraging data
in MBC, it was deemed appropriate to evaluate the role
of ixabepilone in primary disease by using the neoadju-
vant model. A phase 2 trial—incorporating an expression
analysis of genes identiﬁed from a prior clinical investi-
gation as potentially associated with sensitivity/resistance
to ixabepilone—evaluated ixabepilone in the neoadjuvant
setting [54]. Among such genes was MAP-tau (Tau), a well
characterized microtubule stabilizer that is responsible for
the bundling, spacing, and assembly of microtubules. MAP-
tau may compete for taxane binding sites and/or may be
involved in the cooperative binding of paclitaxel to micro-
tubules, therefore potentially having a role in taxanes resis-
tance [58–60].
A total of 161 patients with locally advanced breast
cancer,deﬁnedasprimarydiseaseinthebreastof ≥3cm(T2-
3), were treated with ixabepilone (40mg/m2 IV over 3 hours
every 3 weeks) for 4 or fewer cycles. Of the 161 patients, 42
(26%) had tumors that were TN. Ixabepilone demonstrated
antitumor activity comparable with that reported in trials of
other single agents in the neoadjuvant setting (pCRB= 18%
and overall pCR = 17%). Moreover, the highest ORR, 46.1%,
was observed in patients with aggressive ER-negative/HER2-
positive tumors. These data suggest that ixabepilone may
be particular eﬀective in more aggressive cancer subtypes
(Table 1). Results also conﬁrmed that ER and tau expression
are inversely related to pCRB and ixabepilone sensitivity,
respectively, conﬁrming what was previously observed in
the preclinical setting. The majority of treatment-related
toxicities were manageable and mild-to-moderate, with
severe adverse events reported in nearly one-third of patients
[54]. Grade 3 to 4 neuropathy occurred in ≤3% of patients,
and sensory neuropathy was the most common. Grade 3 to
4 neutropenia was observed in 14% of patients and febrile
neutropenia was reported in 1% of patients (Table 2). As a
neoadjuvant therapy for breast cancer, ixabepilone provided
clinically meaningful beneﬁt and had an acceptable safety
proﬁle.Moreover,theuseofgeneexpressionassayspermitted
the identiﬁcation of patients most likely to beneﬁt from
neoadjuvant ixabepilone treatment based on expression of
the ER and tau biomarkers.
7. Conclusions
The primary goal of treatment of metastatic disease is opti-
mal palliation. The selection of the most appropriate treat-
ment in this setting requires a careful evaluation of tumor
characteristics (disease subtype and location) and patient-
related factors (performance status and toxicity proﬁle). In
fact,thetherapeuticindexforvariousavailableagentsshould
be considered in the selection of treatment to allow for a
more personalized approach. This approach is particularly
important to patients with a limited number of therapeutic
options, such is the case with patients who have TN
MBC. In large prospective clinical trials, ixabepilone has
provided evidence of clinical beneﬁt in this subtype and
a manageable toxicity proﬁle. Moreover, eﬃcacy in taxane
resistance models (β-tubulin overexpression) and the recent
demonstration of the predictive value of tau expression in
primary breast cancer tissue, for example, may possibly
contribute to further reﬁning the selection of patients who
might beneﬁt from ixabepilone as a single agent, or as part
of combination therapy in primary and MBC. Future studies
should explore the role of this drug in neoadjuvant setting
either in combination with biological agents or with other
cytotoxic agents to further assess the impact on patients’
outcome when used in earlier disease.
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